PTC Therapeutics officer sells 23,749 shares
PTC Therapeutics’ Chief Technical Operations Officer Neil Gregory Almstead reported an options exercise and matching share sales in Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics’ Chief Technical Operations Officer Neil Gregory Almstead reported an options exercise and matching share sales in Common Stock. He exercised stock options for 23,749 shares at $25.69 per share, then sold 23,749 shares in open-market transactions at weighted average prices of about $80.61 and $81.21 per share under a written Rule 10b5-1 trading plan adopted on November 11, 2025. He also reports 2,737 shares of Common Stock held indirectly through his spouse.
Insider Trade Summary 10b5-1
Exercise and Sale: 23,749 shares ($1.31M approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Almstead Neil Gregory
Role
CHIEF TECHNICAL OPS OFFICER
Sold
23,749 shs ($1.92M)
Approx. gross sale proceeds
$1.92M
Approx. exercise cost
$610K
Approx. pre-tax spread
$1.31M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 23,749 | $0.00 | $0.00 |
| Exercise | Common Stock | 23,749 | $25.69 | $610K |
| Sale | Common Stock | 12,130 | $80.61 | $978K |
| Sale | Common Stock | 11,619 | $81.21 | $944K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 23,751 contracts (Direct);
Common Stock — 60,137 shares (Direct);
Common Stock — 2,737 shares (Indirect, By Spouse)
Footnotes (4)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
- F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $81.00 to $81.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Key Figures
Shares sold at $81.21: 11,619 shares at $81.21/share
Shares sold at $80.61: 12,130 shares at $80.61/share
Options exercised: 23,749 shares at $25.69/share
+5 more
8 metrics
Shares sold at $81.21
11,619 shares at $81.21/share
Open-market sale of Common Stock on June 22, 2026
Shares sold at $80.61
12,130 shares at $80.61/share
Open-market sale of Common Stock on June 22, 2026
Options exercised
23,749 shares at $25.69/share
Exercise of Stock Option (Right to Buy) into Common Stock
Derivative position after exercise
23,751 options remaining
Stock Option (Right to Buy) following 23,749-share exercise
Indirect spouse holdings
2,737 shares
Common Stock held indirectly by spouse as of June 22, 2026
10b5-1 plan adoption date
November 11, 2025
Date written Rule 10b5-1 trading plan was adopted
Option grant date
February 15, 2024
Grant date of stock option later exercised
Option expiration
February 14, 2034
Expiration date of Stock Option (Right to Buy)
Key Terms
Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.99 per share."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock and 23,749.0000 underlying security shares."
derivative security financial
"Exercise or conversion of derivative security as described in the transaction code description."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect ownership financial
"Common Stock reported with ownership_type indirect and nature_of_ownership By Spouse."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did PTC Therapeutics (PTCT) officer Neil Gregory Almstead report?
Neil Gregory Almstead reported exercising options for 23,749 PTC Therapeutics shares and selling 23,749 shares in open-market trades. The filing also shows 2,737 shares of Common Stock held indirectly through his spouse as of the reported date.
Does Neil Gregory Almstead report any indirect PTC Therapeutics (PTCT) holdings?
Yes. The Form 4 shows 2,737 PTC Therapeutics Common Stock shares reported as indirectly owned "By Spouse." This is separate from his directly held shares and is classified in the filing as indirect ownership with a nature of ownership noted as by spouse.
What are the key terms of Neil Gregory Almstead’s exercised PTC Therapeutics stock option?
The exercised option was granted February 15, 2024, with a $25.69 exercise price and expiration on February 14, 2034. It vests 25% on February 15, 2025, then 6.25% of the original grant every three months starting May 15, 2025, according to the filing footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
